20-3-2007
Maxeda initiates strategic review of HEMA
Maxeda B.V. (“Maxeda”) announces that the Executive Board and SupervisorMaxeda Supervisory
Board have taken the decision last week to start a strategic review which may
result in the sale of its operating subsidiary HEMA B.V. (“HEMA”). The review will be
conducted to investigate the best options to facilitate the future potential of HEMA
outside Maxeda. The strategic review relates to the HEMA subsidiary only.
HEMA is a stand alone company within the Maxeda group, both commercially and
organisationally and has shown consistently strong performance over the past few
years. HEMA is a leader in it’s core markets, and is reaping the benefits from
recent investments and improved business fundamentals.
HEMA has a strong track record of profitable growth as well as excellent
prospects and experienced management. Sales and profitability have grown
consistently over the past three years. Gross sales grew notably to more than EUR
1.3 billion in 2006 with annual double digit operating profit growth. Over the last
years, HEMA has outperformed the non-food retail market and gained market
share.